Atlantic Coastal Acquisition Corp. II (ACAB) Competitors $5.77 -5.13 (-47.06%) (As of 11/12/2024) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ACAB vs. CMPX, HRTX, INZY, TNYA, NBTX, CRBU, KYTX, SCPH, NKTX, and GALTShould you be buying Atlantic Coastal Acquisition Corp. II stock or one of its competitors? The main competitors of Atlantic Coastal Acquisition Corp. II include Compass Therapeutics (CMPX), Heron Therapeutics (HRTX), Inozyme Pharma (INZY), Tenaya Therapeutics (TNYA), Nanobiotix (NBTX), Caribou Biosciences (CRBU), Kyverna Therapeutics (KYTX), scPharmaceuticals (SCPH), Nkarta (NKTX), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. Atlantic Coastal Acquisition Corp. II vs. Compass Therapeutics Heron Therapeutics Inozyme Pharma Tenaya Therapeutics Nanobiotix Caribou Biosciences Kyverna Therapeutics scPharmaceuticals Nkarta Galectin Therapeutics Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap unclassified companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation, earnings and community ranking. Which has better earnings & valuation, ACAB or CMPX? Atlantic Coastal Acquisition Corp. II has higher earnings, but lower revenue than Compass Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/ACompass Therapeutics$850K221.76-$42.49M-$0.37-3.70 Which has more volatility and risk, ACAB or CMPX? Atlantic Coastal Acquisition Corp. II has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Is ACAB or CMPX more profitable? Atlantic Coastal Acquisition Corp. II's return on equity of 0.00% beat Compass Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Atlantic Coastal Acquisition Corp. IIN/A N/A N/A Compass Therapeutics N/A -32.37%-30.67% Does the media refer more to ACAB or CMPX? In the previous week, Compass Therapeutics had 24 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 24 mentions for Compass Therapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.98 beat Compass Therapeutics' score of 0.48 indicating that Atlantic Coastal Acquisition Corp. II is being referred to more favorably in the media. Company Overall Sentiment Atlantic Coastal Acquisition Corp. II Positive Compass Therapeutics Neutral Do analysts prefer ACAB or CMPX? Compass Therapeutics has a consensus price target of $6.75, suggesting a potential upside of 392.70%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Atlantic Coastal Acquisition Corp. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atlantic Coastal Acquisition Corp. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Compass Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the MarketBeat Community believe in ACAB or CMPX? Compass Therapeutics received 30 more outperform votes than Atlantic Coastal Acquisition Corp. II when rated by MarketBeat users. CompanyUnderperformOutperformAtlantic Coastal Acquisition Corp. IIN/AN/ACompass TherapeuticsOutperform Votes3073.17% Underperform Votes1126.83% Do insiders & institutionals believe in ACAB or CMPX? 23.3% of Atlantic Coastal Acquisition Corp. II shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 91.2% of Atlantic Coastal Acquisition Corp. II shares are held by insiders. Comparatively, 28.5% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryCompass Therapeutics beats Atlantic Coastal Acquisition Corp. II on 8 of the 12 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Atlantic Coastal Acquisition Corp. II News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACAB vs. The Competition Export to ExcelMetricAtlantic Coastal Acquisition Corp. IIHolding Offices IndustryUnclassified SectorNASDAQ ExchangeMarket Cap$47.14M$257.55M$111.62M$8.82BDividend YieldN/A7.63%5.21%4.07%P/E RatioN/A9.088.6517.81Price / SalesN/A119.820.9774.56Price / CashN/A84.56103.1432.53Price / BookN/A91.26519.864.68Net IncomeN/A$32.24M$2.82M$226.08M7 Day PerformanceN/A-0.21%-0.19%-1.04%1 Month Performance-48.02%-4.81%-3.22%1.04%1 Year Performance-45.57%14.31%15.40%26.28% Atlantic Coastal Acquisition Corp. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACABAtlantic Coastal Acquisition Corp. IIN/A$5.77-47.1%N/A-45.6%$47.14MN/A0.004High Trading VolumeCMPXCompass Therapeutics3.4259 of 5 stars$1.37-3.5%$6.75+392.7%-18.9%$188.50M$850,000.00-3.7020HRTXHeron Therapeutics3.9688 of 5 stars$1.12-5.9%$5.67+406.0%-13.8%$180.99M$137.74M-6.22300Analyst DowngradeShort Interest ↓INZYInozyme Pharma1.2302 of 5 stars$2.79-0.7%$15.71+463.2%-28.5%$180.51MN/A0.0050TNYATenaya Therapeutics3.9666 of 5 stars$2.22-2.2%$14.75+564.4%+18.4%$179.83MN/A0.00110Gap UpNBTXNanobiotix2.3367 of 5 stars$4.07+7.7%$11.50+182.7%-33.5%$178.16M$39.18M0.00100Positive NewsCRBUCaribou Biosciences2.9283 of 5 stars$1.96-1.5%$11.25+474.0%-64.7%$177.48M$11.48M-1.19100KYTXKyverna Therapeutics2.8357 of 5 stars$4.12+1.0%$25.71+524.1%N/A$176.14M$7.03M0.0096Analyst ForecastAnalyst RevisionGap UpSCPHscPharmaceuticals3.8122 of 5 stars$3.36-4.5%$15.00+346.4%-40.2%$176.14M$13.59M0.0030Analyst RevisionNKTXNkarta2.1933 of 5 stars$2.50+0.8%$16.50+560.0%-4.4%$175.01MN/A0.00140GALTGalectin Therapeutics1.6982 of 5 stars$2.82+2.2%$11.00+290.8%+50.8%$172.91MN/A0.009Analyst UpgradeAnalyst RevisionNews Coverage Related Companies and Tools Related Companies CMPX Alternatives HRTX Alternatives INZY Alternatives TNYA Alternatives NBTX Alternatives CRBU Alternatives KYTX Alternatives SCPH Alternatives NKTX Alternatives GALT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACAB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atlantic Coastal Acquisition Corp. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Atlantic Coastal Acquisition Corp. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
